Wedbush Reaffirms Outperform Rating for Aprea Therapeutics with $7 Price Target

Wedbush reaffirms its Outperform rating and $7 price target for Aprea Therapeutics. The company's lead product candidates, APR-1051 and ATRN-119, are in Phase 1 and Phase 1/2a clinical trials, respectively. Aprea has entered a $30 million private placement financing and reported positive clinical activity for APR-1051 in the ongoing Phase 1 trial. Analyst Robert Driscoll views the confirmed response as validation for APR-1051 in patients with genetically defined cancers. APRE is currently trading at $0.78, up 5.98%.